Our previous studies have shown increased activation markers such as CD69 and CD154 on T cells from MS patients compared to healthy controls, either ex vivo without stimulation or after in vitro stimulation as in the current paper [56]. This evidence concerns the gene CD69 and myeloid sarcoma.